Biocon markets CytoSorb in India

On the occasion of World Sepsis Day, Biocon launched CytoSorb here in Bangalore, which is claimed to be the first-in-class novel therapy for sepsis management.


CytoSorb - A first-in-class novel therapy for sepsis management

Biocon has entered into a strategic partnership with CytoSorbents Corp., having exclusive commercialization rights for CytoSorb in India and other emerging markets. However, the financial terms of the agreement were not disclosed.

Kiran Mazumdar Shaw, chairperson and managing director of Biocon said, "We believe our partnership with CytoSorbents will enable us to address the huge unmet need of sepsis management in India and emerging markets. CytoSorb is a ‘first-in-class'therapy that can provide an effective solution to physicians to treat critically ill patients suffering from sepsis. This move reflects our commitment to bring differentiated products to India that will help address various healthcare challenges faced by millions of patients in our country."

According to Biocon, CytoSorb is a safe and effective extra-corporeal cytokine filter, designed to target prevention or treatment of organ failure, which is found to be the cause for half of all deaths in intensive care units (ICUs). When left unchecked, ‘cytokine storm' caused by excessive cytokine production causes massive inflammation, organ failure and death in common life-threatening conditions such as sepsis, burn injury, trauma, lung injury, and pancreatitis.

"We are very pleased to enter into this initial agreement with Biocon on World Sepsis Day to bring our potentially life-saving therapy to the people of India and other emerging markets. Unlike any other previous approach, CytoSorb attacks sepsis from multiple angles by reducing cytokine storm and deadly bacterial toxins, and directing immune cells to target the infection while avoiding damage to otherwise healthy organs," said Dr Phillip Chan, chief executive officer and president of CytoSorbents.

CytoSorb is claimed to bear the CE Mark regulatory approval, and is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50 percent. It also works easily with standard dialysis machines used in hospitals, said the press release.

It is said that Biocon and CytoSorbents will initially focus on treating sepsis, which is the end result of an excessive immune response to an infection. By amalgamating Biocon's critical care antibiotics in treating the infection, which is compatible with CytoSorb therapy in modulating the immune response, the two companies are aiming to provide a holistic solution for sepsis management in the market.

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email